Testing CT-95 in advanced cancers with mesothelin
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that shows a protein called mesothelin (your doctor can check this).
- You are well enough to be up and about (fully active or able to do light work).
- Your cancer can be measured with scans (like CT or MRI).
- Your organs (like liver, kidneys, bone marrow) are working well.
- You have not had a prior treatment that targets mesothelin (like CAR-T cells or a CD3-based drug).
- You are not currently in another experimental drug trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and attack cancer cells showing a protein called mesothelin. It may be an option for people with advanced solid tumors who have exhausted standard treatments.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
This trial tests a new treatment that uses your own immune cells (T cells) engineered to find and attack cancer cells that have a protein called mesothelin on their surface. It is for people with advanced or recurrent esophagogastric cancer (cancer of the esophagus or stomach) or malignant peritoneal mesothelioma (a rare cancer of the lining of the abdomen). The treatment involves collecting your T cells, modifying them in a lab, and then giving them back to you after a short course of chemotherapy to help them work.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
This trial tests a new treatment called KT032, a type of CAR-T cell therapy, for people with advanced solid tumors (like ovarian cancer, mesothelioma, or colon cancer) that have spread to the belly lining. The treatment is given as an injection and is designed to target a protein called mesothelin on cancer cells. The goal is to see if it's safe and if it can help shrink tumors.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.